CareDx said it entered a definitive agreement to acquire Naveris for up to $260 million, combining CareDx’s precision oncology testing footprint with Naveris’ liquid biopsy capabilities in HPV-driven cancers. The deal includes $160 million upfront cash, plus up to $100 million tied to revenue milestones. Naveris operates high-complexity clinical laboratories in Massachusetts and North Carolina and markets NavDx, a tumor-naïve minimal residual disease (MRD) test that measures viral DNA fragments in blood to detect HPV-driven cancers and support disease management. CareDx said NavDx received Medicare coverage in 2023 and that Naveris has completed more than 130,000 commercial tests to date. CareDx’s CEO John Hanna emphasized the acquisition is targeted to a specific viral-mediated cancer space already embedded in reimbursed workflows, not a broad MRD expansion across the company’s portfolio.